Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma

NCT01982097 · clinicaltrials.gov ↗

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Sorafenib (Nexavar, BAY 43-9006)

Sponsor

Bayer